Syllabi/Slides for this program are a supplement to the live CME session and are not intended for other purposes.
|
|
- Domenic Mosley
- 5 years ago
- Views:
Transcription
1 Learning Objectives Understand and appropriately individualize treatments based on evidencebased guideline recommendations across the continuum of care in patients with T2DM Key = Clinical Pearl Identify and address both patient and clinician barriers to using injectable therapies in patients with T2DM in an effort to easily adopt therapy, increase medication adherence, and improve overall outcomes Utilize a pathophysiologic approach to intensify therapy with the combination of GLP-1 RAs and basal insulin in patients not achieving glycemic control, including the use of fixed-dose combinations to improve adherence Importance of Glycemic Control UKPDS Individualizing HbA1c Targets for Patients with T2DM ACCORD and VADT suggested increased risk from intensive glycemic control in high risk patients 12% 14% 21% 19% For Every 1% Reduction in HbA1C 37% 16% 43% 14% 21% ACCORD, ADVANCE, and VADT found NO significant reduction in adverse CV outcomes with intensive glycemic control in patients with more advanced T2DM Stratton IM et al. BMJ. 2;321: Diabetes Care 218 Jan; 41 (Supplement 1): S55-S64.
2 ADA Framework for Considering Glycemic Goals in Older Adults with Diabetes Patient Characteristics/Health Status Rationale Reasonable HbA1c Goal Healthy (few coexisting chronic illnesses, intact cognitive and functional status) Complex/intermediate (multiple coexisting chronic illnesses* or 2+ instrumental ADL impairments or mild-to-moderate cognitive impairment) Very complex/poor health (LTC or end-stage chronic illnesses** or moderate-to-severe cognitive impairment or 2+ ADL dependencies) Adapted from ADA. Diabetes Care. 218: 41(1):21, Table Longer remaining life expectancy Intermediate remaining life expectancy, high treatment burden, hypoglycemia vulnerability, fall risk Limited remaining life expectancy makes benefit uncertain <7.5% <8.% <8.5% *Coexisting chronic illnesses are conditions serious enough to require medications or lifestyle management. **The presence of a single end-stage chronic illness may cause significant symptoms or impairment of functional status and significantly reduce life expectancy. Patient-Centered Care Improves: Patient care Cost Patient knowledge Shared decision making Adapted from Oshima Lee E, Emanuel EJ. N Engl J Med. 213;368(1):6-8; Wilson SR, et al. Am J Respir Crit Care Med. 21;181(6): Patient outcomes Adherence AACE/ACE Glycemic Control Algorithm AACE/ACE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM. AACE/ACE. Garber AJ, et al. Endocr Pract. 218;24(1): ADA Treatment Recommendations A1C is less than 9%, consider monotherapy A1C is greater than or equal to 9%, consider dual therapy A1C is 1%, blood glucose is 3 mg/dl, or a patient is markedly symptomatic consider combination injectable therapy Monotherapy Lifestyle Management + Metformin Initiate metformin therapy if no contraindications A1C at target after 3 months of monotherapy? Monitor A1C every 3-6 Assess medication-taking behavior months Consider Dual therapy Dual Therapy Lifestyle Management + Metformin + Additional Agent ASCVD? Add agent proven to reduce major adverse CV events and/or CV mortality Combination Injectable Therapy Adapted from ADA. Diabetes Care. 218: 41(1):S Add second agent after consideration of drug-specific effects and patient factors A1C at target after 3 Monitor A1C every 3-6 Assess medication-taking behavior months of dual therapy? months Consider Triple therapy Triple Therapy Lifestyle Management + Metformin + Two Additional Agents Add a third agent based on drug-specific effects and patient factors A1C at target after 3 months of triple therapy? Monitor A1C every 3-6 months Assess medication-taking behavior Consider Combination Injectable therapy
3 Patient Case of Uncontrolled T2DM Patient Case of Uncontrolled T2DM John is a 6-year-old man diagnosed with T2DM six years ago. Medical history: Surgical History: He feels well and expresses no concerns at today s routine office visit. T2DM 6 years HTN Lasik Appendectomy John, age 6 He is compliant with his current medications He checks his FPG sometimes and reports a range of mg/dl He tries to exercise 2-3 times a week but has trouble finding the time John, age 6 Hyperlipidemia Obesity BPH Social History: Denies tobacco ~2 drinks/week Patient Case of Uncontrolled T2DM Patient Case of Uncontrolled T2DM John, age 6 Medications: Metformin 1 mg BID Glimepiride 4 mg QD Lisinopril 4 mg QD Metoprolol 1 mg BID Atorvastatin 4 mg QD Tamsulosin.4 mg QD Aspirin 81 mg QD John, age 6 Vitals: Temp 98.7 F HR 56 bpm RR 16 BP 13/84 mmhg Ht 72 inches Wt 25 lbs BMI 34 kg/m² WC 45 inches Allergies: NKDA
4 Relevant Labs (fasting) HbA1c 8.8% Fasting Plasma Glucose 185 mg/dl Limitations of Oral Antidiabetic Medications Many patients fail to achieve glycemic goals with initial monotherapy¹ John, age 6 LDL HDL BUN 12 mg/dl 45 mg/dl 2 mg/dl Of those who do achieve their goals, few consistently maintain these targets over three years due to lack of durability¹ Creatinine 1.4 mg/dl egfr 5 ml/min/1.73m² What s Next? In when oral therapy fails, is contraindicated, or is not recommended such with elevated entry HbA1c patients often require injectable therapies to help achieve glycemic control 1,2 1. McColloch DK. Accessed Apr 5 217; 2. ADA. Diabetes Care. Jan 217; 4(Suppl 1); 3. Garber AJ, et al. Endocr Pract. 217; 23(2): AACE/ACE Glycemic Control Algorithm AACE/ACE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM. AACE/ACE. Garber AJ, et al. Endocr Pract. 218;24(1): ADA Treatment Recommendations A1C is less than 9%, consider monotherapy A1C is greater than or equal to 9%, consider dual therapy A1C is 1%, blood glucose is 3 mg/dl, or a patient is markedly symptomatic consider combination injectable therapy Monotherapy Lifestyle Management + Metformin Initiate metformin therapy if no contraindications A1C at target after 3 months of monotherapy? Monitor A1C every 3-6 Assess medication-taking behavior months Consider Dual therapy Dual Therapy Lifestyle Management + Metformin + Additional Agent ASCVD? Add agent proven to reduce major adverse CV events and/or CV mortality Combination Injectable Therapy Adapted from ADA. Diabetes Care. 218: 41(1):S Add second agent after consideration of drug-specific effects and patient factors A1C at target after 3 Monitor A1C every 3-6 Assess medication-taking behavior months of dual therapy? months Consider Triple therapy Triple Therapy Lifestyle Management + Metformin + Two Additional Agents Add a third agent based on drug-specific effects and patient factors A1C at target after 3 months of triple therapy? Monitor A1C every 3-6 months Assess medication-taking behavior Consider Combination Injectable therapy
5 Patient Barriers to Injectable Therapy Overcoming Patient Barriers to Injection Perceptions of hypoglycemia Associated with poor outcomes/ diabetic complications Associated with failure Ascertain and acknowledge the patient s fears Simple regimen (once daily) Convenience and accuracy -pens Concerns about restricted, burdensome lifestyle Believe that it portends worsening disease Have patient demonstrate injection in office Educate on lifestyle modifications/diabetes educator Allow patients to self-titrate medication Customize treatment plan for each patient Cultural taboos Cost Injection pain/phobia Provide written instructions Injectable medication as a solution, not a threat To overcome concerns of weight gain, combo basal insulin and GLP-1 RA ADA. Diabetes Care. Jan 217; 4(Suppl 1). Karter AJ, et al. Diabetes Care. 21; 33(4): Funnell MM. Clinical Diabetes. 27;25(1):36-38; Peyrot M, et al. Primary Care Diabetes. 21;4(Suppl 1):S11-S18; Unger J. Diabetes Metab Syndr Obes. 211;4: ; Zisman A, et al. ADA Scientific Sessions. San Diego, CA P. Clinician Barriers to Injectable Therapy Time constraints Lack of support/resources Perceived inadequacy of blood glucose monitoring Fear of poor patient adherence Actual patient non-adherence Concern about adverse events from insulin such as hypoglycemia Lack of knowledge of guidelines and injectable medication options/use/mechanism of action/benefits Pathophysiology of T2DM Progressive β cell failure Elevated post prandial glucose (PPG) Subsequent rise in fasting plasma glucose (FPG) Glucose overproduction in the liver during basal state Impaired suppression of hepatic glucose production by insulin Impaired glucose uptake in the muscle after carbohydrate ingestion Smith RJ, et al. J Clin Endocrinol Metab. 21;95(4): Frei A, et al. Cardiovasc Diabetol. 21;9:23. Martin D, et al. Pediatr Diabetes. 212;13 Suppl16:2-28. DeFronzo RA, et al. Diabetes Care. 213;36 Suppl 2:S
6 The Physiologic Insulin Profile Basal Insulin / MoA Serum insulin (mu/l) Mealtime insulin excursions Rapid rise; short duration Smooth, steady basal insulin profile Suppresses hepatic glucose secretion Accounts for approx. 4-5% of total daily insulin requirements Keeps plasma glucose stable in absence of food Breakfast Lunch Dinner 4 8 Adapted from Kruszynska Y, et al. Diabetologia. 1987;3:16. Advantages of Basal Insulin Basal Insulins Long acting Basal Insulin Type Onset Peak Duration of Action (h) Variability Once daily Flat biologic profile with minimal peaks Intermediate-acting Human NPH 1-2 h 4-12 h 1-24 h Greater Insulin glargine (U-1) (Lantus, Basaglar) Long-acting analogs Insulin detemir (Levemir) h 1.1 h No pronounced peak No pronounced peak 7.6 to >24 Less 6 to >24 Less Lower risk of hypoglycemia, especially nocturnal Ultra-long-acting analogs Insulin glargine U-3 (Toujeo) Insulin degludec (U-1/U-2) (Tresiba) Less variability = Less hypoglycemia 6 h Nearly peakless >36 h Minimal 3-9 min Nearly peakless >42 Minimal Hirsch IB. N Engl J Med. 25;352(2): Meneghini L. et al. Diabetes Obes Metab. 27;9(6): PL Detail-Document, Comparison of Insulins and Injectable Diabetes Meds. Pharmacist s Letter/Prescriber s Letter. March 215; PDR.net. Accessed Jan 26, 218; PDR.net. Accessed Jan 26, 218; Tresiba package insert. Accessed Jan 3, 218. Fiasp package insert. Accessed Jan 26, 218; Monami M, et al. Diabetes Res Clin Pract. 28;81(2): ; Marso SP et al. N Engl J Med 217;377:
7 Insulin Initiation AACE/ACE ADA Initiate Basal Insulin Usually with metformin ± other noninsulin agent Start: 1 U/day or.1-.2 U/kg/day Adjust: 1-15% or 2-4 units once or twice weekly to reach FBG target For hypo: Determine & address cause; if no clear reason for hypo dose by 4 units or 1-2% Monitoring HbA1c every 3 months Check FPG daily Check PPG 2 hrs after meals if concern for PPG elevations AACE/ACE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM. AACE/ACE. Garber AJ, et al. Endocr Pract. 218;24(1): Adapted form ADA. Diabetes Care. 218: 41(1):S Patient Case of Uncontrolled T2DM John s Weekly BG Log John, age 6 Metformin 1 mg BID Glimepiride 4 mg QD Glargine 6 units John was initiated on basal insulin six months ago. The dose of insulin glargine was titrated up to 6 U/day. HbA1C = 7.4% FPG range mg/dl PPG range 18-3mg/dL What would you recommend NEXT? Time of Day Saturday Sunday Monday Tuesday Wednesday Thursday Friday Pre Post Pre Post Pre Post Pre Post Pre Post Pre Post Pre Post Breakfast Lunch Dinner Bedtime On two occasions in the afternoon when feeling weak and hungry, John checked his BG and it was <7 mg/dl (62 and 67 mg/dl)
8 Hypoglycemia and Medication Adherence ADA / Insulin Algorithm If A1C not controlled, consider combination injectable therapy Add 1 rapid-acting insulin injection before largest meal Start: 4 units,.1 U/kg, or 1% basal dose. If A1C <8%, consider basal by same amount Adjust: dose by 1-2 units or 1-15% once or twice weekly until SMBG target reached For hypo: Determine and address cause; if no clear reason for hypo, corresponding dose by 2-4 units or 1-2% Add GLP-1RA If not tolerated or A1C target not reached, change to 2 injection insulin regimen If goals not met, consider changing to alternative insulin regimen Change to premixed insulin twice daily (before breakfast and supper) Start: Divide current basal dose into 2/3 am, 1/3 PM or ½ am, ½ PM Adjust: dose by 1-2 units or 1-15% once or twice weekly until SMBG target reached For hypo: Determine and address cause; if no clear reason for hypo, corresponding dose by 2-4 units or 1-2% Hajós TR. Diabetes Care. 214;37(1): Gonder-Frederick LA. Diabet Med. 213;3(5): Adapted from ADA. Diabetes Care. 218: 41(1):S Leveraging the Incretin Effect of GLP-1 Central nervous system Promotes satiety and reduction of appetite GLP-1 Receptor Agonists Excess glucose production Liver: glucagon reduces hepatic glucose output Glucagon excess α-cell glucagon secretion post-meal Impaired beta-cell function Enhances glucose-dependent insulin secretion and β-cell functional mass Stomach Regulates gastric emptying Flint A, et al. J Clin Invest. 1998;11(3): Larsson H, et al. Acta Physiol Scand. 1997;16(4): Nauck MA, et al. Diabetologia. 1996;39(12): Drucker DJ. Diabetes. 1998;47(2):
9 FDA Approved GLP-1 RAs GLP-1 RAs Added to Metformin Medication Exenatide BID Lixisenatide Liraglutide Exenatide QW Trade name Duration Adverse Events Dosing Byetta Adlyxin Victoza Bydurion Short-acting Long-acting Nausea, vomiting, dyspepsia Nausea, vomiting, diarrhea, headache Nausea, vomiting, diarrhea, headache, dyspepsia, fatigue Nausea, diarrhea, headache, dyspepsia, vomiting Dulaglutide Trulicity Nausea, diarrhea, vomiting Semaglutide Ozempic Nausea, vomiting, diarrhea, constipation, abdominal pain Start 5 mcg twice daily (1 h before morning and evening meals), may increase to 1 mcg after 1 mo Start 1 mcg daily (1 h before 1 st meal of day), may increase to 2 mcg daily after 14 d Start.6 mg once daily, may increase to 1.2 mg after 1 wk. Max dose 1.8 mg daily 2 mg once wk Start.75 mg once weekly, may increase to 1.5 mg once wk Start.25 mg once wk, may increase to.5 mg once wk. Max dose 1 mg wk Δ HbA1c,% EXE BID EXE QW PLB LIRA 1.8 mg PLB LIXI EXE BID -1 P< P = NI DULA 1.5 DULA.75 mg mg -.71 P<.1 SITA -.32 SEMA.5 DULA.75 SEMA 1 mg mg mg DULA 1.5 mg Byetta. Summary of Product Characteristics; 2. Lyxumia. Summary of Product Characteristics; 3. Victoza. Summary of Product Characteristics; 4. Marbury T et al. Diabetes 214;63(Suppl.1):A26(11-P); 5. Kapitza C et al. J Clin Pharm 215;55:497 54; 6. Barrington et al. Diabetes Obes Metab 211;13: ; 7. Fineman M et al. Clin Pharmacokinet 211;5:65 74; 8. Ozempic prescribing information; 9. Trulicity prescribing information. P<.1 P< NI = non-inferior P<.1 DeFronzo RA, et al. Diabetes Care. 25;28(8):192-11; (2) Bergenstal RM, et al. Lancet. 21;376: (3) Nauck M, et al. Diabetes Care. 29;32(1):84-9. (4) Ahren B, et al. Diabetes Care. 214;37(8): (5) Weinstock RS, et al. Diabetes Obes Metab 215; 17:849. (6) Rosenstock J. Diabetes Care. 213 Oct;36(1): (7) Pratley R, et al. Lancet Diabetes Endocrinol GLP-1 RAs: Comparative Change in Weight Advantages of GLP-1 RAs Baseline Weight avg 95 LEAD-6 Duration-1 Duration-6 AWARD-1 AWARD-6 LIRA-LIXI SUSTAIN-7 Change in Weight (kg) p= p=.89 p=.1 Buse JB et al. Lancet. 29;374:39 47 (LEAD-6); Drucker DJ et al. Lancet. 28;372:124 5 (DURATION-1); (3) Buse JB et al. Lancet. 213;381: (DURATION-6); Pratley RE et al. Lancet Diabetes Endocrinol. 214;2: (Harmony-7); Wysham C et al. Diabetes Care. 214;37(8): (AWARD-1); Dungan KM et al. Lancet. 214; 384(9951): (AWARD-6). Nauck M et al. Diabetes Care. 216 Sep;39(9):151-9; Pratley R, et al. Lancet Diabetes Endocrinol. 218 (SUSTAIN 7) p= p< p< p<.1 Liraglutide 1.8 mg Exenatide 1 µg BID Exenatide 2 mg QW Dulaglutide 1.5 mg Lixisenatide Semaglutide 1. mg Lower HbA1c (1-2%)¹ Lower rates of Hypoglycemia Weight loss (2-5 kg)¹ Decreased post-prandial glucose (more with short-acting agents)¹ Decrease cardiovascular risk factors (blood pressure, lipids, hs-crp) Drucker DJ, Nauck MA. Lancet. 26;368(9548): ; Baggio LL, Drucker DJ. Gastroenterology. 27;132(6): ; American Diabetes Association. Diabetes Care. 215;38(suppl MA.. 1):S41-S48.
10 Cardiovascular Benefit of GLP-1 RAs Lixisenatide (ELIXA) and exenatide (EXSEL) showed no adverse CV outcomes Liraglutide (LEADER) and Semaglutide (SUSTAIN-6) showed CV benefit Albiglutide (Harmony Outcomes) showed CV benefit Not being marketed in the US Dulaglutide (REWIND) ongoing trial Pfeffer MA, et al. N Engl J Med. 215;373: cardiovascular-safety.html; Accessed January 17, 217. Marso SP, et al. N Engl J Med. 216;375(4): Marso SP, et al. N Engl J Med. 216;375(19): , Hernandez, A, et al. Lancet. Oct 2, 218. DOI: GLP-1 Contraindications and Warnings Warning/ contraindication Do not use if history of MTC or MEN2 History of pancreatitis Increased risk of hypoglycemia with secretagogues/ insulin Serious Hypersensitivity Exenatide BID (Byetta) Consider other agents Exenatide QW (Bydureon) Liraglutide (Victoza) Lixisenatide (Adlyxin) Dulaglutide (Trulicity) Semaglutide (Ozempic) X X X X Consider other agents Consider other agents Consider other agents Consider other agents Consider other agents X X X X X X X X X X X X Do not use if X X X severe GI disease MEN2, multiple endocrine neoplasia syndrome type 2; MTC, medullary thyroid carcinoma; GI, gastrointestinal Lixisenatide 5. Albiglutide 6) Dulaglutide 7. semaglutide Avoiding Nausea with GLP-1 RAs Renal Dosing of GLP-1 RAs Educate on meal size, eating pace, and dose timing relative to meals Short-acting GLP-1 RAs should be taken within 6 minutes before morning and evening meals Avoid taking a GLP-1 RA close to a large or high fat meal, as this may cause nausea Use incremental dose titration, particularly with shorter-acting agents Renal Status Mild impairment (CrCl 5-8 ml/min) Moderate impairment (CrCl 3-5 ml/min) Severe impairment (CrCl <3 ml/min) ESRD Exenatide BID (Byetta) Exenatide QW (Bydureon) No adjustment or recommendation Use caution when initiating or escalating doses Use with caution Should not be used Liraglutide (Victoza) No dose adjustment Use caution when initiating or escalating doses Semaglutide & Dulaglutide (Ozempic & Trulicity) No dose adjustment Monitor renal function in patients with renal impairment reporting severe adverse gastrointestinal reactions Lixisenatide (Adlyxin) Use caution but no dose adjustment Renal transplant Use with caution Ellero C, et al. Diabet Med. 21;27(1): Adapted from prescribing information for Byetta, Bydureon, Victoza, Ozempic, Trulicity, Adlyxin.
11 Selecting the Ideal GLP-1 RA PPG Effect of Short- and Long-Acting GLP-1 RAs The selection of GLP-1 RA depends on individual pharmacokinetics/pharmacodynamics of each agent Long acting GLP 1 RAs dulaglutide, liraglutide, exenatide QW, semaglutide Have a preferential effect on lowering FPG Short acting agents lixisenatide and exenatide BID Have a preferential effect on lowering PPG Mean Change from Pre-Meal Plasma Glucose, mg/dl Liraglutide (Baseline) Lixisenatide (Baseline) Liraglutide (Day 28) Lixisenatide (Day 28) Meal GLP-1 RA Time Post Administration Holst JJ, Vilsbøll T. Diabetes Obes Metab. 213;15(1):3-14. Kapitza C, et al. Diabetes Obes Metab. 213;15(7): Patient Case of Uncontrolled T2DM John, age 6 HbA1c = 7.4% FPG = mg/dl PPG = 18 3mg/dL Metformin 1 mg BID Glargine 6 units Because John has elevated PPG, a short-acting GLP-1 RA is the best choice. John is receptive to adding a GLP-1 RA but asks if he really needs to also continue on the basal insulin as he is reluctant to have another daily injection Complementary Action Addresses Underlying Pathophysiologic Defects in T2DM 5 6% HbA1c goal attained Simple to initiate Modest weight gain Hypoglycemia risk lower than NPH Decreases FPG and nocturnal hypoglycemia Basal Insulin GLP 1 RAs 4 6% HbA1c goal attained Simple to initiate Weight loss No increase in hypoglycemia Decreases PPG (short acting) Little S, et al. Diabetes Technol Ther. 211:13(suppl 1):S53-S64; Cohen ND, et al. Med J Australia. 213;199(4): ; Carris NW, et al. Drugs. 214;74(18):
12 Approved Fixed-Ratio GLP-1 RA/Basal Insulin Formulations Drug Brand Name Insulin to GLP 1 RA Ratio Supplied As Insulin Glargine/Lixisenatide Soliqua 1 Unit/.33 mcg 3 ml prefilled pen 1/33 (iglarlixi) Insulin Degludec/Liraglutide 1/3.6 (ideglira) Xultophy 1 Unit/.36 mg 3 ml prefilled pen Less Frequent Injection = Improved Adherence Persistence With GLP-1 RA at 1 Year, % Once-daily injection 73 UK 64 Twice-daily injection Germany Accessed December 18, Accessed December18, Wilke T, et al. Diabetes Ther. 216;7:15-124; Garber AJ. Lancet Diabetes Endocrinol. 214;2: ; Kirkman MS, et al. Diabetes Care. 215;38: Effects of Lixisenatide, iglarlixi, and Glargine on Glucose Levels Difference (mg/dl) 95% CI Mean (95% CI) Change From Baseline (mg/dl) iglarlixi (n=468) FPG (-7.6,.7) (-4.5, -3.3) -59. Glargine (n=466) -27. Lixi (n=233) iglarlixi (n=468) Glargine affects FPG, Lixisenatide affects PPG Rosenstock J, Aronson R, Grunberger G, et al. Diabetes Care. 216;39(11): hr PPG Excursions (-45., -31.9) (8.1, 24.8) -3.2 Glargine (n=466) Lixi (n=233) iglarlixi in Insulin-Naive Patients with T2DM HbA1c (%) * iglarlixi 1/33 (n=469) 75% of patients achieved an HbA1c < 7% 32% of patients who achieved an HbA1c < 7% had no symptomatic hypoglycemia and did not gain weight Change From Baseline at Week 3 Glargine (n=467) *p<.1; p<.5; p<.1 compared with Glar/Lixi 1/33; PPG changes are mean for all three meals. Rosenstock J, Aronson R, Grunberger G, et al. Diabetes Care. 216;39(11): * Lixisenatide (n=234) Baseline Week 3 59% of patients achieved an HbA1c < 7% 19% of patients who achieved an HbA1c < 7% had no symptomatic hypoglycemia and did not gain weight 33% of patients achieved an HbA1c < 7%
13 iglarlixi Trials: Changes in Weight ideglira in Insulin Naive Patients With T2DM Change From Baseline at Week 26 Weight Change, kg Insulin-Naive Patients with T2DM iglarlixi 1/33 Glargine Lixisenatide P <.1 Weight Change, kg Patients with T2DM Not Controlled with Basal Insulin iglarlixi 1/ Glargine.7 % HbA1c ideglira 1/3.6 (n=833) 81% of patients achieved an HbA1c < 7% Degludec (n=413) 65% of patients achieved an HbA1c < 7% Liraglutide (n=414) 6% of patients achieved an HbA1c < 7% Baseline Week 3 Rosenstock J, Aronson R, Grunberger G, et al. Diabetes Care. 216;39(11): ; Aroda VR, et al. Diabetes Care. 216;39(11): Gough SC, et al. Lancet Diabetes Endocrinol. 214;2(11): ideglira in Insulin Naive Patients with T2DM Changes in Weight Initiating GLP-1 RA/Basal Insulin Therapy Weight Change, kg Insulin Naive Patients with T2DM ideglira 1/3.6 Degludec Liraglutide Weight Change, kg Patients with T2DM Not Controlled by Insulin ideglira 1/3.6 Degludec First: Down-titrate basal insulin dose Gough SC, et al. Lancet Diabetes Endocrinol. 214;2(11):
14 Initiating Insulin iglarlixi (Xultophy) Therapy Titrating iglarlixi (Xultophy) Pen Ratio of iglarlixi in 3 ml prefilled pen is 1 Unit/.33 mcg (1/33) The lowest possible dose of iglarlixi is 15 Units/5 mcg (for patients inadequately controlled on < 3 Units of basal insulin, insulin naive patients, or patients not controlled on lixisenatide) 3 Units/1 mcg starting dose for patients inadequately controlled on 3-6 Units of insulin daily Dose should be given 1 hour prior to 1 st meal of the day If FPG is above target, increase 2U every week If FPG is below target, decrease 2U every week Maximum dose is 6 U/2 mcg Accessed December 18, Accessed December 18, 217. Initiating Insulin ideglira (Soliqua) Therapy Titrating Insulin ideglira (Soliqua) Pen Ratio of ideglira in 3 ml prefilled pen is 1 Unit/.36 mg Recommended starting dose is 16 Units/.58 mg Regardless of whether patient was previously on insulin (even though the lowest possible dose is 1 Units/.36 mg) Regardless of the patients previous basal insulin dose If FPG is above target, increase 2 Units every 3-4 days If FPG is below target, decrease 2 Units every 3-4 days Maximum dose is 5 Units/1.8 mg Accessed December 18, Accessed December 18, 217.
15 Patient Case of Uncontrolled T2DM John returns after three months on 45 Units / 15 mcg of iglarlixi. John, age 6 Metformin 1 mg BID iglarlixi 45 U/ 15 mcg HbA1c = 6.6%. FPG = mg/dl PPG = mg/dl HbA1c = 6.6%. PPG = mg/dl. No hypoglycemic episodes. He has lost another 2 lbs and feels great.
GLP-1 receptor agonists for type 2 diabetes currently available in the U.S.
GLP-1 receptor agonists for type 2 diabetes currently available in the U.S. GLP-1 agonists are a class of antidiabetic agents that mimic the actions of the glucagon-like peptide. GLP-1 is one of several
More informationUpdate on Insulin-based Agents for T2D
Update on Insulin-based Agents for T2D Injectable Therapies for Type 2 Diabetes Mellitus (T2DM) and Obesity This presentation will: Describe established and newly available insulin therapies for treatment
More informationGLP-1 RECEPTOR AGONIST SHOULD I TRY IT? VERONICA BRADY, PHD, BC-ADM, CDE PROJECT ECHO JUNE 21, 2018
GLP-1 RECEPTOR AGONIST SHOULD I TRY IT? VERONICA BRADY, PHD, BC-ADM, CDE PROJECT ECHO JUNE 21, 2018 SOMETHING TO CONSIDER IF YOU COULD PRESCRIBE A MEDICATION FOR YOUR PATIENT WITH DIABETES THAT: DECREASED
More informationInitiating Injectable Therapy in Type 2 Diabetes
Initiating Injectable Therapy in Type 2 Diabetes David Doriguzzi, PA C Learning Objectives To understand current Diabetes treatment guidelines To understand how injectable medications fit into current
More informationINJECTABLE THERAPY FOR THE TREATMENT OF DIABETES
INJECTABLE THERAPY FOR THE TREATMENT OF DIABETES ARSHNA SANGHRAJKA DIABETES SPECIALIST PRESCRIBING PHARMACIST OBJECTIVES EXPLORE THE TYPES OF INSULIN AND INJECTABLE DIABETES TREATMENTS AND DEVICES AVAILABLE
More informationIncredible Incretins Abby Frye, PharmD, BCACP
Incredible Incretins Abby Frye, PharmD, BCACP Objectives & Disclosures Review the pathophysiology of T2DM and the impact of the incretin system Describe the defining characteristics of the available glucagonlike
More informationGlucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol
Glucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed
More informationWhat s New in Type 2 Diabetes? 2018 Diabetes Updates
What s New in Type 2 Diabetes? 2018 Diabetes Updates Gretchen Ray, PharmD, PhC, BCACP, CDE Associate Professor, UNM College of Pharmacy January 28, 2018 gray@salud.unm.edu OBJECTIVES Describe the most
More informationUpdate on New Basal Insulins and Combinations: Starting, Titrating and Adding to Therapy
Update on New Basal Insulins and Combinations: Starting, Titrating and Adding to Therapy Jerry Meece, BPharm, CDE, FACA, FAADE Director of Clinical Services Plaza Pharmacy and Wellness Center Gainesville,
More informationGLP-1 (glucagon-like peptide-1) Agonists (Byetta, Bydureon, Tanzeum, Trulicity, Victoza ) Step Therapy and Quantity Limit Criteria Program Summary
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) s (Byetta/exenatide, Bydureon/ exenatide extended-release, Tanzeum/albiglutide, Trulicity/dulaglutide, and Victoza/liraglutide) Step Therapy
More informationBasal & GLP-1 Fixed Combination Use
Basal & GLP-1 Fixed Combination Use Michelle M. Mangual, MD Diplomate of the American board of Internal Medicine and Endocrinology, Diabetes and Metabolism San Juan City hospital Learning Objectives o
More informationNewer Insulins. Boca Raton Regional Hospital 15th Annual Internal Medicine Conference
Newer Insulins Boca Raton Regional Hospital 15th Annual Internal Medicine Conference Luigi F. Meneghini, MD, MBA Professor of Internal Medicine, UT Southwestern Medical Center Executive Director, Global
More informationThe first stop for professional medicines advice
London Medicines Evaluation Network Overview: Glucagon-Like Peptide-1 receptor analogues The first stop for professional medicines advice 1 London Medicines Evaluation Network Overview: Glucagon-Like Peptide-1
More informationGLP-1 agonists. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
GLP-1 agonists Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What do GLP-1 agonists do? Physiology of postprandial glucose regulation Meal ❶ ❷ Insulin Rising plasma
More informationGLP-1-based therapies in the management of type 2 diabetes
GLP-1-based therapies in the management of type 2 diabetes Makbul Aman Mansyur Division Endocrine & Metabolism Department of Internal Medicine Faculty of Medicine Hasanuddin University/ RSUP Dr. Wahidin
More informationBeyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM
Beyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM Disclosures Jennifer D Souza has no conflicts of interest to disclose. 2 When Basal Insulin Is Not Enough Learning
More informationNext Generation Diabetes Management:
Next Generation Diabetes Management: Titratable Fixed-Ratio Combination Therapy with Basal Insulin/GLP-1 RA to Better Manage Type 2 Diabetes Supported by an educational grant from Sanofi US Learning Objectives
More informationDiabetes Update: Intensifying Insulin Therapy Nuts, Bolts and Other Items
Diabetes Update: Intensifying Insulin Therapy Nuts, Bolts and Other Items Hayley A. Miller, MD Physician, Internal Medicine, Diabetes and Metabolism, Sandy Clinic, Intermountain Healthcare Objectives:
More informationUKPDS: Over Time, Need for Exogenous Insulin Increases
UKPDS: Over Time, Need for Exogenous Insulin Increases Patients Requiring Additional Insulin (%) 60 40 20 Oral agents By 6 Chlorpropamide years, Glyburide more than 50% of UKPDS patients required insulin
More informationManagement of Type 2 Diabetes
Management of Type 2 Diabetes Pathophysiology Insulin resistance and relative insulin deficiency/ defective secretion Not immune mediated No evidence of β cell destruction Increased risk with age, obesity
More informationAdvances in Outpatient Diabetes Care: Algorithms for Care and the Role of Injectable Therapies. Module D
Advances in Outpatient Diabetes Care: Algorithms for Care and the Role of Injectable Therapies Module D 1 Learning Objectives Apply the principles of the comprehensive diabetes algorithms to patients with
More informationCardiovascular Benefits of Two Classes of Antihyperglycemic Medications
Cardiovascular Benefits of Two Classes of Antihyperglycemic Medications Nathan Woolever, Pharm.D., Resident Pharmacist Pharmacy Grand Rounds November 6 th, 2018 Franciscan Healthcare La Crosse, WI 2017
More informationSelecting GLP-1 RA Treatment
Selecting GLP-1 RA Treatment Dr Felicity Kaplan March 2017 Objectives Review the progressive nature of type 2 diabetes Understand the need for timely treatment intensification Examine the place of GLP-1
More informationComprehensive Diabetes Treatment
Comprehensive Diabetes Treatment Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism The George Washington University School of Medicine Diabetes
More informationAgenda. Indications Different insulin preparations Insulin initiation Insulin intensification
Insulin Therapy F. Hosseinpanah Obesity Research Center Research Institute for Endocrine sciences Shahid Beheshti University of Medical Sciences November 11, 2017 Agenda Indications Different insulin preparations
More informationI have no financial incentives or conflicts of interest to disclose for this presentation.
Jacob Lenzmeier, PharmD Resident Pharmacist-CentraCare Health November 9, 2017 1 I have no financial incentives or conflicts of interest to disclose for this presentation. 2 1 Review the mechanism of action,
More informationWhat s New in Type 2 Diabetes? 2018 Diabetes Updates
What s New in Type 2 Diabetes? 2018 Diabetes Updates Jessica Conklin, PharmD, PhC, BCACP, CDE, AAHIP Associate Professor, UNM College of Phar macy jeconklin@salud.unm.edu Luis Gonzales, PharmD, PhC UNM
More informationDisclosure. Learning Objectives. Case. Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare
Disclosure Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare Spring Therapeutics Update 2011 CSHP BC Branch Anar Dossa BScPharm Pharm D CDE April 20, 2011
More informationDiabetes: Three Core Deficits
Diabetes: Three Core Deficits Fat Cell Dysfunction Impaired Incretin Function Impaired Appetite Suppression Obesity and Insulin Resistance in Muscle and Liver Hyperglycemia Impaired Insulin Secretion Islet
More informationInjectable Agents for Type 2 Diabetes. Richard Christensen, MD AACE Diabetes Day, Boise, ID September 2017
Injectable Agents for Type 2 Diabetes Richard Christensen, MD AACE Diabetes Day, Boise, ID September 2017 Financial Disclosures Sanofi speaker honoraria No other relevant financial disclosures Injectable
More informationFaculty. Timothy S. Reid, MD (Co-Chair, Presenter) Medical Director Mercy Diabetes Center Janesville, WI
Activity Overview In this case-based webcast, meet Jackie, a 62-year-old woman with type 2 diabetes. Her glycated hemoglobin (HbA1C) is 9.2%, and she is taking 2 oral agents and basal insulin; however,
More informationGLUCAGON LIKE PEPTIDE (GLP) 1 AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES, WEIGHT CONTROL AND CARDIOVASCULAR PROTECTION.
GLUCAGON LIKE PEPTIDE (GLP) 1 AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES, WEIGHT CONTROL AND CARDIOVASCULAR PROTECTION. Patricia Garnica MS, ANP-BC, CDE, CDTC Inpatient Diabetes Nurse Practitioner North
More informationTimely!Insulinization In!Type!2! Diabetes,!When!and!How
Timely!Insulinization In!Type!2! Diabetes,!When!and!How, FACP, FACE, CDE Professor of Internal Medicine UT Southwestern Medical Center Dallas, Texas Current Control and Targets 1 Treatment Guidelines for
More informationAchieving and maintaining good glycemic control is an
Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE; Kathleen Wyne, MD, PhD, FACE, FNLA; Anthony Cannon,
More informationThis program applies to Commercial, GenPlus and Health Insurance Marketplace formularies.
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) Agonists [Adlyxin (lixisenatide), Byetta (exenatide), Bydureon (exenatide extended-release), Tanzeum (albiglutide), Trulicity (dulaglutide),
More informationProgressive Loss of β-cell Function in T2DM
Disclaimer This slide deck in its original and unaltered format is for educational purposes and is current as of November 2015. The content and views presented in this educational activity are those of
More informationPresented By: Creative Educational Concepts, Inc. Lexington, KY
Disclaimer This slide deck in its original and unaltered format is for educational purposes and is current as of April 2015. The content and views presented in this educational activity are those of the
More informationErtugliflozin (Steglatro ) 5 mg daily. May increase to 15 mg daily. Take in the morning +/- food. < 60: Do not initiate; discontinue therapy
Sodium-glucose Cotransporter-2 (SGLT2) s Inhibit SGLT in proximal renal tubules, reducing reabsorption of filtered glucose from tubular lumen Lowers renal threshold for glucose à increase urinary excretion
More informationA Practical Approach to the Use of Diabetes Medications
A Practical Approach to the Use of Diabetes Medications Juan Pablo Frias, M.D., FACE President, National Research Institute, Los Angles, CA Clinical Faculty, University of California, San Diego, CA OUTLINE
More informationApplication of the Diabetes Algorithm to a Patient
Application of the Diabetes Algorithm to a Patient Apply knowledge gained from this activity to improve disease management and outcomes for patients with T2DM and obesity Note: The cases in this deck represent
More informationModulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes
Modulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes Geneva Clark Briggs, PharmD, BCPS Adjunct Professor at University of Appalachia College of Pharmacy Clinical Associate, Medical
More informationMOA: Long acting glucagon-like peptide 1 receptor agonist
Alexandria Rydz MOA: Long acting glucagon-like peptide 1 receptor agonist Increases glucose dependent insulin secretion Decreases inappropriate glucagon secretion Increases β- cell growth and replication
More informationApproaches to Addressing Incretin Deficiency. Non-Insulin Injectable Agents. Incretin Mimetics. Exendin-4 in the Gila Monster
Non-Insulin Injectable Agents Approaches to Addressing Incretin Deficiency Longer-acting analogs? (Incretin mimetics) GLP-1 Analogs Inhibition of inactivation? (Incretin enhancers) DPP-4 Inhibitors Drucker
More informationDM-2 Therapy Update: GLP-1, SGLT-2 Inhibitors, and Inhaled Insulin, Oh My!
DM-2 Therapy Update: GLP-1, SGLT-2 Inhibitors, and Inhaled Insulin, Oh My! Kevin M. Pantalone, DO, ECNU, CCD Associate Staff Director of Clinical Research Department of Endocrinology Endocrinology and
More informationLet s not sugarcoat it! Update on Pharmacologic Management of Type II DM
Let s not sugarcoat it! Update on Pharmacologic Management of Type II DM Gregory Castelli, PharmD, BCPS, BC-ADM Clinical Pharmacist UPMC St. Margaret Objectives By the end of this presentation, participants
More informationOptimizing Treatment Strategies to Improve Patient Outcomes in the Management of Type 2 Diabetes
Optimizing Treatment Strategies to Improve Patient Outcomes in the Management of Type 2 Diabetes Philip Raskin, MD Professor of Medicine The University of Texas, Southwestern Medical Center NAMCP Spring
More information9/6/18. Clinical Updates for Nurse Practitioners and Physician Assistants: Faculty. Disclosures
Clinical Updates for Nurse Practitioners and Physician Assistants: 218 Combination Basal Insulin and GLP-1 RA Therapy: A Physiologic Approach to Diabetes Care Faculty Robert S. Busch, MD, FACE Director
More informationThe New Age of Insulin: Exploring the Latest Trends in Insulin Therapy. The New Age of Insulin: Exploring the Latest Trends in Insulin Therapy
The New Age of Insulin: Exploring the Latest Trends in Insulin Therapy Susan Cornell, PharmD, CDE, FAPhA, FAADE Associate Director of Experiential Education Associate Professor of Pharmacy Practice Midwestern
More informationInsulin Initiation and Intensification. Disclosure. Objectives
Insulin Initiation and Intensification Neil Skolnik, M.D. Associate Director Family Medicine Residency Program Abington Memorial Hospital Professor of Family and Community Medicine Temple University School
More informationADA and AACE Glycemic Targets
ADA and AACE Glycemic Targets HbA1C target should be individualized based on a number of factors including: Age Life expectancy Comorbidities Duration of diabetes Risk of hypoglycemia Patient motivation
More informationIndividualizing Care for Patients with Type 2 Diabetes
Individualizing Care for Patients with Type 2 Diabetes Disclosures Speaker: AstraZeneca, Novo Nordisk, BI/Lilly, Valeritas, Takeda Advisor: Tandem Diabetes, Sanofi Objectives Develop individualized approaches
More information5/16/2018. Insulin Workshop. Disclosures to Participants. Learning Objectives. This presentation will cover the following learning objectives:
Insulin Workshop Joshua J. Neumiller, PharmD, CDE, FASCP Vice Chair & Associate Professor, Department of Pharmacotherapy Washington State University Spokane, WA Holly Divine, PharmD, BCACP, BCGP, CDE,
More informationUpdate on Therapies for Type 2 Diabetes: Angela D. Mazza, DO July 31, 2015
Update on Therapies for Type 2 Diabetes: 2015 Angela D. Mazza, DO July 31, 2015 Objectives To present the newer available therapies for the management of T2D To discuss the advantages and disadvantages
More informationNew Drug Evaluation: Dulaglutide
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More information5/16/2018. Insulin Update: New and Emerging Insulins. Disclosures to Participants. Learning Objectives
Insulin Update: New and Emerging Insulins Joshua J. Neumiller, PharmD, CDE, FASCP Vice Chair & Associate Professor, Department of Pharmacotherapy Washington State University Spokane, WA Disclosures to
More informationSTEP THERAPY CRITERIA
CATEGORY DRUG CLASS BRAND NAME (generic) STEP THERAPY CRITERIA AMYLIN ANALOG: SYMLIN/SYMLINPEN (pramlintide acetate) ANTIDIABETIC AGENTS GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1): ADLYXIN (lixisenatide)
More informationGLP-1 Receptor Agonists and SGLT-2 Inhibitors. Debbie Hicks
GLP-1 Receptor Agonists and SGLT-2 Inhibitors Debbie Hicks Prescribing and Adverse Event reporting information is available at this meeting from the AstraZeneca representative The views expressed by the
More information3/8/2011. Julie M. Sease, Pharm D, BCPS, CDE Associate Professor of Pharmacy Practice Presbyterian College School of Pharmacy
Summarize revisions to the 2011 American Diabetes Association clinical practice guidelines. Evaluate bromocriptine as a therapeutic option in the management of type 2 diabetes. Compare and contrast the
More informationPathogenesis of Type 2 Diabetes
9/23/215 Multiple, Complex Pathophysiological Abnmalities in T2DM incretin effect gut carbohydrate delivery & absption pancreatic insulin secretion pancreatic glucagon secretion HYPERGLYCEMIA? Pathogenesis
More informationDiabetes Meds Update Disclaimer and Important Info. Objectives. Page 1. Copyright , Diabetes Education Services
Diabetes Meds Update 2016 Beverly Dyck Thomassian, RN, MPH, BC ADM, CDE President, Diabetes Education Services Disclaimer and Important Info This content is for educational purposes only. Please see Package
More informationAlbiglutide, a Once-Weekly GLP-1RA, for the Treatment of Type 2 Diabetes
St. Onge et al. Medical Research Archives, vol. 5, issue 11, November 2017 issue Page 1 of 10 REVIEW ARTICLE Albiglutide, a Once-Weekly GLP-1RA, for the Treatment of Type 2 Diabetes Erin St. Onge 1*, Shannon
More informationFrancesca Porcellati
XX Congresso Nazionale AMD Razionali e Benefici dell Aggiunta del GLP-1 RA Short-Acting all Insulina Basale Francesca Porcellati Dipartimento di Medicina Interna, Sezione di Medicina Interna, Endocrinologia
More informationIntensifying Treatment Beyond Monotherapy in T2DM: Where Do Newer Therapies Fit?
Intensifying Treatment Beyond Monotherapy in T2DM: Where Do Newer Therapies Fit? Vanita R. Aroda, MD Scientific Director & Physician Investigator MedStar Community Clinical Research Center MedStar Health
More information10/15/18. Clinical Updates for Nurse Practitioners and Physician Assistants: Faculty. Disclosures
Clinical Updates for Nurse Practitioners and Physician Assistants: 2018 Combination Basal Insulin and GLP-1 RA Therapy: A Physiologic Approach to Diabetes Care Faculty Robert S. Busch, MD, FACE Director
More informationConvenience of Fixed-Ratio Basal Insulin GLP-1 RA Combination Therapy
Convenience of Fixed-Ratio Basal Insulin GLP-1 RA Combination Therapy Xavier Cos Catalonian Health Institute Barcelona, Spain Stewart B. Harris Western University London, ON, Canada Basal Insulin GLP-1
More informationChief of Endocrinology East Orange General Hospital
Targeting the Incretins System: Can it Improve Our Ability to Treat Type 2 Diabetes? Darshi Sunderam, MD Darshi Sunderam, MD Chief of Endocrinology East Orange General Hospital Age-adjusted Percentage
More informationWhat s New? An Antihyperglycemic Medications Update
What s New? An Antihyperglycemic Medications Update WADE 2016 Annual Conference Josh Neumiller, PharmD, CDE, FASCP Associate Professor Department of Pharmacotherapy Washington State University Disclosures
More informationPractical Strategies for the Clinical Use of Incretin Mimetics CME/CE. CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010
Practical Strategies for the Clinical Use of Incretin Mimetics CME/CE Robert R. Henry, MD Authors and Disclosures CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010 Introduction Type 2 diabetes
More informationPHARMACOLOGIC APPROACH TO ACHIEVE GLYCEMIC GOAL
Dr Aurora Alcantara Endocrinology PHARMACOLOGIC APPROACH TO ACHIEVE GLYCEMIC GOAL SPED Convention and Diabetes Postgraduate Course May26-29 Wyndham Grand Rio Mar, PR DISCLOSURES Speaker for the following
More informationLilly Diabetes: Pipeline Update
Lilly Diabetes: Pipeline Update June 16, 2014 Safe Harbor Provision This presentation contains forward-looking statements that are based on management's current expectations, but actual results may differ
More informationIncretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
Incretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors Timothy Bailey, MD, FACE, CPI Director, AMCR Institute,
More informationClinical Policy: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Reference Number: HIM.PA.53 Effective Date: Last Review Date: 02.
Clinical Policy: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Reference Number: HIM.PA.53 Effective Date: 03.01.18 Last Review Date: 02.19 Line of Business: HIM Revision Log See Important Reminder
More informationEmerging Challenges in Primary Care: GLP-1 Receptor Agonists: New Insights and New Strategies for Successful Long-Term Diabetes Management
Emerging Challenges in Primary Care: 2017 GLP-1 Receptor Agonists: New Insights and New Strategies for Successful Long-Term Diabetes Management 1 Faculty Richard S. Beaser, MD Senior Staff Physician, Medical
More informationEarly treatment for patients with Type 2 Diabetes
Israel Society of Internal Medicine Kibutz Hagoshrim, June 22, 2012 Early treatment for patients with Type 2 Diabetes Eduard Montanya Hospital Universitari Bellvitge-IDIBELL CIBERDEM University of Barcelona
More informationWhat's New in Insulin Related Therapies 2018
What's New in Insulin Related Therapies 2018 James Lenhard, MD (JLenhard@ChristianaCare.org) Section Chief, Endocrinology and Metabolism Christiana Care Health System Newark, DE Disclosures Speaker:Eli
More informationBrigham and Women s Hospital Type 2 Diabetes Management Program Physician Pharmacist Collaborative Drug Therapy Management Protocol
Brigham and Women s Hospital Type 2 Diabetes Management Program Physician Pharmacist Collaborative Drug Therapy Management Protocol *Please note that this guideline may not be appropriate for all patients
More informationObjectives. Recognize all available medical treatment options for diabetes. Individualize treatment and glycemic target based on patient factors
No disclosure Objectives Recognize all available medical treatment options for diabetes Individualize treatment and glycemic target based on patient factors Should be able to switch to more affordable
More informationWhat the Pill Looks Like. How it Works. Slows carbohydrate absorption. Reduces amount of sugar made by the liver. Increases release of insulin
Diabetes s Oral s - Pills These are some of the pills that are currently available in Canada to treat diabetes. Each medication has benefits and side effects you should be aware of. Your diabetes team
More informationOBESITY IN TYPE 2 DIABETES
OBESITY IN TYPE 2 DIABETES Ashley Crowl, PharmD, BCACP Assistant Professor University of Kansas Objectives Review how to manage obesity in patients with type-2 diabetes mellitus Compare antiobesity agents
More informationSoliqua (insulin glargine and lixisenatide), Xultophy (insulin degludec and liraglutide)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.48 Subject: Insulin GLP-1 Combinations Page: 1 of 5 Last Review Date: September 15, 2017 Insulin GLP-1
More informationDEMYSTIFYING INSULIN THERAPY
DEMYSTIFYING INSULIN THERAPY ASHLYN SMITH, PA-C ENDOCRINOLOGY ASSOCIATES SCOTTSDALE, AZ SECRETARY, AMERICAN SOCIETY OF ENDOCRINE PHYSICIAN ASSISTANTS ARIZONA STATE ASSOCIATION OF PHYSICIAN ASSISTANTS SPRING
More informationThe Highlights of the AWARD Clinical Program FRANCESCO GIORGINO
The Highlights of the AWARD Clinical Program FRANCESCO GIORGINO DEPARTMENT OF EMERGENCY AND ORGAN TRANSPLANTATION SECTION OF INTERNAL MEDICINE, ENDOCRINOLOGY, ANDROLOGY AND METABOLIC DISEASES Disclaimer
More informationLearning Objectives. Impact of Diabetes II UPDATES IN TYPE 2 DIABETES. David Doriguzzi, PA-C
UPDATES IN TYPE 2 DIABETES David Doriguzzi, PA-C Learning Objectives Upon completion of this educational activity, the participant should be able to: Overcome barriers and attitudes that limit Clinician/Patient
More informationWhat to Do After Basal Insulin
BasalINSULIN What to Do After Basal Insulin 3 Treatment Strategies for Type 2 Diabetes These strategies can help you optimize glucose control in your patient with type 2 diabetes when basal insulin alone
More informationPramlintide & Weight. Diane M Karl MD. The Endocrine Clinic & Oregon Health & Science University Portland, Oregon
Pramlintide & Weight Diane M Karl MD The Endocrine Clinic & Oregon Health & Science University Portland, Oregon Conflict of Interest Speakers Bureau: Amylin Pharmaceuticals Consultant: sanofi-aventis Grant
More informationDrug List. Drug List (cont.) Objectives. Case 1 Bruce. Presenter Disclosure Information
1:15 :3 PM GLP-1 Receptor Agonists and Basal Insulin Combination: A Complementary Strategy for Type Diabetes Treatment Intensification SPEAKERS Vivian Fonseca, MD Dace Trence, MD, FACE Presenter Disclosure
More informationINSULIN 101: When, How and What
INSULIN 101: When, How and What Alice YY Cheng @AliceYYCheng Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form
More informationUpdate on Insulin-based Agents for T2D. Harry Jiménez MD, FACE
Update on Insulin-based Agents for T2D Harry Jiménez MD, FACE Harry Jiménez MD, FACE Has received honorarium as Speaker and/or Consultant for the following pharmaceutical companies: Eli Lilly Merck Boehringer
More informationPharmacology Updates. Quang T Nguyen, FACP, FACE, FTOS 11/18/17
Pharmacology Updates Quang T Nguyen, FACP, FACE, FTOS 11/18/17 14 Classes of Drugs Available for the Treatment of Type 2 DM in the USA ### Class A1c Reduction Hypoglycemia Weight Change Dosing (times/day)
More informationExploring Non-Insulin Therapies in Type 1 Diabetes
Exploring Non-Insulin Therapies in Type 1 Diabetes Susan Cornell, BS, PharmD, CDE, FAPhA, FAADE Associate Professor Midwestern University - Chicago College of Pharmacy Disclosures Dr. Cornell: Advanced
More informationAdlyxin. (lixisenatide) New Product Slideshow
Adlyxin (lixisenatide) New Product Slideshow Introduction Brand name: Adlyxin Generic name: Lixisenatide Pharmacological class: Glucagon-like peptide-1 (GLP-1) receptor agonist Strength and Formulation:
More informationMYTH VS FACT #1: GLP-1 RECEPTOR AGONISTS SHOULD BE RESERVED FOR PATIENTS WITH LONG-STANDING T2DM
9:45 11: AM Separating Myth from Fact: The Role of Receptor Agonists for the Treatment of T2DM SPEAKERS James R. Gavin, III, MD, PhD John E. Anderson, MD Presenter Disclosure Information The following
More informationMultiple Factors Should Be Considered When Setting a Glycemic Goal
Multiple Facts Should Be Considered When Setting a Glycemic Goal Patient attitude and expected treatment effts Risks potentially associated with hypoglycemia, other adverse events Disease duration Me stringent
More informationType 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions
Diabetes Mellitus: Complications and Co-Morbid Conditions ADA Guidelines for Glycemic Control: 2016 Retinopathy Between 2005-2008, 28.5% of patients with diabetes 40 years and older diagnosed with diabetic
More informationMYTH VS FACT #1: GLP-1 RECEPTOR AGONISTS SHOULD BE RESERVED FOR PATIENTS WITH LONG-STANDING T2DM
15 mins for presentation & ARS MYTH VS FACT #1: GLP-1 RECEPTOR AGONISTS SHOULD BE RESERVED FOR PATIENTS WITH LONG-STANDING T2DM Carol Hatch Wysham, MD Clinical Associate Professor of Medicine University
More informationTips and Tricks for Starting and Adjusting Insulin. MC MacSween The Moncton Hospital
Tips and Tricks for Starting and Adjusting Insulin MC MacSween The Moncton Hospital Progression of type 2 diabetes Beta cell apoptosis Natural History of Type 2 Diabetes The Burden of Treatment Failure
More informationInitiation and Titration of Insulin in Diabetes Mellitus Type 2
Initiation and Titration of Insulin in Diabetes Mellitus Type 2 Greg Doelle MD, MS April 6, 2016 Disclosure I have no actual or potential conflicts of interest in relation to the content of this lecture.
More informationXultophy 100/3.6. (insulin degludec, liraglutide) New Product Slideshow
Xultophy 100/3.6 (insulin degludec, liraglutide) New Product Slideshow Introduction Brand name: Xultophy Generic name: Insulin degludec, liraglutide Pharmacological class: Human insulin analog + glucagon-like
More informationBasal-Bolus Insulin Therapy. Veronica Brady, PhD, FNP-BC, BC-ADM, CDE ECHO January
Basal-Bolus Insulin Therapy Veronica Brady, PhD, FNP-BC, BC-ADM, CDE ECHO January 18 2018 Terminology No longer using the term diabetic. Diabetes does not define people. People with diabetes are individuals
More information